Novo Nordisk Expecting Slower Growth In China
This article was originally published in PharmAsia News
Executive Summary
Despite a solid first quarter in China, Novo Nordisk is predicting a slowdown in its growth in the country as the general compliance crackdown dampens promotional activities across the pharma industry.